3 September 2021 - Late treatment study
Evaluation of low-dose aspirin use among COVID-19 critically ill patients: A Multicenter Propensity Score Matched Study
et al., Research Square, doi:10.21203/rs.3.rs-872891/v1 (Preprint)
Retrospective 1,033 critical condition patients, showing lower in-hospital mortality with aspirin in PSM analysis. Patients receiving aspirin also had a higher risk of significant bleeding, although not reaching statistical significance. Authors note that the use of aspirin during an ICU stay should be tailored to each patient.
|
risk of death, 27.0% lower, RR 0.73, p = 0.03, treatment 98 of 176 (55.7%), control 107 of 173 (61.8%), NNT 16, adjusted per study, in-hospital mortality, multivariable Cox proportional hazards.
|
|
risk of death, 14.0% lower, RR 0.86, p = 0.30, treatment 95 of 176 (54.0%), control 97 of 175 (55.4%), NNT 69, adjusted per study, day 30, multivariable Cox proportional hazards.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Al Harthi et al., 9/3/2021, retrospective, propensity score matching, Saudi Arabia, Middle East, preprint, 20 authors.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.